Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.
2026 could be a big year for this company.
AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...
Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...
Vinay Prasad is tightening the screws at the FDA, overruling staff and signaling a tougher stance on vaccines and gene ...
The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...
Eli Lilly will acquire Orna Therapeutics for up to $2.4 billion to gain access to the Watertown biotech's circular RNA ...
The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...
The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...
Zacks Investment Research on MSN
Here's why IO Biotech, Inc. (IOBT) looks ripe for bottom fishing
Shares of IO Biotech, Inc. (IOBT) have been struggling lately and have lost 31.1% over the past four weeks. However, a hammer ...
Get the latest federal technology news delivered to your inbox. The congressional working group on the national security ramifications of biotechnology is angling to publish and deliver new policy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results